SRP3182
VEGF human
Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Sinônimo(s):
Folliculostellate cell-derived growth factor, Glioma-derived endothelial cell mitogen, VPF, Vascular Endothelial Growth Factor-A
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Código UNSPSC:
12352202
NACRES:
NA.32
Produtos recomendados
fonte biológica
human
recombinante
expressed in E. coli
Ensaio
≥98% (HPLC)
≥98% (SDS-PAGE)
forma
lyophilized
potência
1.0-8.0 ng/mL
peso molecular
38.2 kDa
embalagem
pkg of 10 μg
técnica(s)
cell culture | mammalian: suitable
Impurezas
<0.1 EU/μg endotoxin, tested
cor
white
nº de adesão UniProt
Condições de expedição
wet ice
temperatura de armazenamento
−20°C
Informações sobre genes
human ... VEGFA(7422)
Categorias relacionadas
Descrição geral
VEGF (vascular endothelial growth factor) signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant human VEGF is a 38.2kDa disulfide-linked homodimeric protein consisting of two 165 amino acid polypeptide chains.
Aplicação
VEGF human has been used as a chemoattractant for HUVECs (human umbilical vein endothelial cells) migration assay.
Ações bioquímicas/fisiológicas
VEGF (vascular endothelial growth factor) is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intraocular neovascular syndromes. Polymorphism in VEGF at C(-634)G is linked with diabetic retinopathy in type 2 diabetes.
Sequência
APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR
forma física
Lyophilized with no additives.
Reconstituição
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a stabilizer (example 5% Trehalose) and store in working aliquots at -20°C to -80°C.
Código de classe de armazenamento
11 - Combustible Solids
Classe de risco de água (WGK)
WGK 3
Ponto de fulgor (°F)
Not applicable
Ponto de fulgor (°C)
Not applicable
Certificados de análise (COA)
Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Os clientes também visualizaram
Naoki Horikawa et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 23(2), 587-599 (2016-07-13)
High VEGF expression in ovarian cancer is an unfavorable prognostic factor. However, the role of VEGF in tumor immunity remains unclear. Here, we examined the impact of VEGF on local immunity, including induction of myeloid-derived suppressor cells (MDSC), in ovarian
Ca2+ influx through reverse mode Na+/Ca2+ exchange is critical for vascular endothelial growth factor-mediated extracellular signal-regulated kinase (ERK) 1/2 activation and angiogenic functions of human endothelial cells.
Andrikopoulos P
The Journal of Biological Chemistry, 286, 37919-37931 (2011)
Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa.
Andre T
International Journal of Cancer. Journal International Du Cancer, 86, 174-181 (2000)
VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis.
Hirakawa S
The Journal of Experimental Medicine, 20, 1089-1099 (2005)
M Clauss et al.
The Journal of experimental medicine, 172(6), 1535-1545 (1990-12-01)
Systemic infusion of low concentrations of tumor necrosis factor/cachectin (TNF) into mice that bear TNF-sensitive tumors leads to activation of coagulation, fibrin formation, and occlusive thrombosis exclusively within the tumor vascular bed. To identify mechanisms underlying the localization of this
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica